CENTRE FOR BIO SEPARATION TECHNOLOGY (CBST)
Projects
The research and development activities will be focused on the following interconnected themes:
- Separation Science – Chromatography and allied analytical techniques, Molecular Recognitions, Microfluids devices, Mass Spectrometry and Proteomics
- Immunotechnology- Diagnostics and Bio-therapeutic antibodies
- Bioactive molecules from plant extracts
- Recombinant protein expressions
- Metabolic Disorders – Diabetes, Cardio vascular disorders, Obesity
- Drug designing and development, Structural biology
- DEPARTMENT OF SCIENCE & TECHNOLOGY (DST), Govt. of India, Under the High Priority Area of Research.
- DEPARTMENT OF BIOTECHNOLOGY programme support on improved production and processing of therapeutic proteins.
- DEPARTMENT OF SCIENCE & TECHNOLOGY: Engineering of beta-glucosidases for improved yield of glycoconjugates (collaboration with IIT Delhi).
- PALL, European Operations: Study and evaluation of new chromatographic supports.
- TIFAC, Govt. of India, New Delhi. Development of novel process in isolating standardized extract of Aloe vera and its application for diabetes control. Bioprocess and Bioproducts Programme.
International
| S.No | Title | PI/Co-PI | Funding agency | Period & Amount | Status |
| 1 | Oxidized HDL-Apolipprotein A1 as a risk predictor of cardiovascular disorders and development of novel diagnostics | Dr. Krishnan V, Dr. Jaya Praksah N. S., Prof.Xavier Santarelli University of Bordeaux, Bordeaux, France Dr.Daniela Balvay, SPAN Diagnostics, Compiegene, France Ms.Supriya Kashikar Genext Genomics Nagpur | BIRAC-CEFIPRA-French Embassy | 2014-2017 (3 Years) Rs. 22,86,057 | Completed |
| 2 | Cost-effective strategy for the induction of immune tolerance to therapeutic factor VIII in haemophilia A | Dr Krishnan V Dr.Sebastien Lacroix, INSERM, CRC, Paris, Frane Dr.Daniela Balvay, SPAN Diagnostics, Compiegene, France Dr.Murali Tummuru Virchow Biotech Pvt Ltd Hyderabad | CEFIPRA | 2017-2020 (3 years) Rs. 57,36,366 | Completed |
| 3 | Phase I: Synthesis of poly(ethylene oxide dendrimers and chemical modification with current cancer drugs Phase II: Drug conjugate PEO dendrimers in vivo validation | Dr. Vijayalakshmi M A Dr. T. Kali Kishore Reddy Dr. Yves Gnanou (KAUST) | KAUST | 2016-2019 (3 Years) $1,18,000 | Completed |
| 4 | Phase II: Drug conjugate PEO dendrimers in vivo validation | Dr. Vijayalakshmi M A Dr. T. Kali Kishore Reddy Dr. Yves Gnanou (KAUST) | KAUST | 2018-2020 | Completed |
National
| S.No | Title | PI/Co-PI | Funding agency | Period & Amount | Status |
| 1 | Advanced centre for Bioseparations and related Technologies (SR/CBST (Phase II)/IRHPA/2009) | Prof. M. A. Vijayalakshmi | DST | 2012-2017 | Completed |
| 2 | Evaluation of applicability of different arginine-modifying tags for middle-downproteomics by electrospray mass spectrometry | Dr. V Sabareesh | SERB-DST (Young Scientist Scheme) | 2014-2017 (3 Years) Rs. 21,00,000 | Completed |
| 3 | The immuno-psychiatry in south india study (IPS): Immunogenetic andimmunophenotype characterization of major sychoses | Dr. M. A. Vijayalakshmi Dr. A. S. Kamalanathan | CEFIPRA | 2014-2017 (3 years) Rs. 3,00,000 | Completed |
| 4 | Immobilized metal-ion affinity(IMA)microfluidic system for probing proteins at molecular and cellular levels | Dr. T. Kali Kishore Reddy | SERB-DST (Young Scientist Scheme) | 2015-2018 (3 years) Rs25,97,000 | Completed |
| 5 | Structural studies of plant pathogenesis related proteins | Dr Sanjit Kumar | SERB-DST (Young Scientist Scheme) | 2014-2016 (2 years) Rs. 13,21,700 | Completed |
| 6 | ldentification of the latent tuberculosis specific marker by the immunoploteomlcanalysjs of the cell wall and membrane proteins of M. tuberculosis | Dr. Jayaprakash N S | SERB-DST (EMR scheme) | 2018-2021 (3 years) Rs. 23,96,600 | Completed |
| 7 | A simple and robust microchip to screen post translational modifications inHuman plasma | Dr. T. Kali Kishore Reddy Dr. Sanjit Kumar | SERB-DST (CRG scheme) | 2019-2022 (3 years) Rs. 28,60,440 | Completed |
| 8 | Development of a rapid diagnostic platform to detect antibodies to Salmonellatyphi using a synthetic & unique Salmonella specific outer membrane antigenfragment | Dr. Jayaprakash N S | ICMR | 2019-2021 (2 years) Rs. 18,30,000 | Completed |
| 9 | Structure based inhibitors design for Lpx-H(UDP-diacylglucosaminepyrophosphohydrolase) involved in gram negative bacterial lipid A biosynthesis | Dr. Sanjit Kumar Dr. T. Kali Kishore Reddy | ICMR | 2019-2022 (3 years) | Completed |
| 10 | Development of Novel Process for Aloe vera extract and its Development as a Therapeutic Treatment for Diabetes | Dr. M. A. Vijayalakshi, Dr. Krishnan V, Dr. Ayesha Noor | BIOTIFAC-DST | 2011-2014 (3 Years) Rs. 60,58, 000 | Completed |
| 11 | A simple microfluidic diagnostic chip for rapid and sensitive evaluation of Vitamin D deficiency. | Dr T. Kali Kishore Reddy & Dr. Sanjit Kumar | DBT | 2019-2022 (3 years) Rs. 36,45,120 | Completed |
| 12 | High yielding cell line development of a Factor VIII biosimilar with a novel purification strategy | Prof. Krishnan V, & Prof. M. A. Vijayalakshmi Collaboration Amthera Life Sciences Pvt Limited, Bangalore (Dr.Susobhan Das, CEO) | BIRAC | 2020-2022 (2 years) Rs. 369.19 lakhs | Completed |
| 13 | Development of benzothiazole-derivatives grafted microfluidic device for Screening of Amyloids | Dr. Priyankar Sen, Dr. Kali Kishore Reddy Tetala | ICMR | 2020-2021 (1 Year) Rs. 10, 00,000 | Completed |
| 14 | Development of a monoclonal antibody-based diagnostic method for the specific detection of COVID-19 viral antigens | Dr. Jayaprakash N.S. / Prof. Krishnan V | DBT-BIRAC | 2020-2022(15 months) Rs.58.93 lakhs | Completed |
| 15 | Development and trial of potential inhibitors of Biofilm formation in MDR bacteria: Novel approach to combat nosocomial infections | Dr. Sanjit Kumar | ICMR | 2020-2023 (3 years) Rs. 37 Lakhs | On-going |
| 16 | Ligand Targeted PROTAC Conjugates: Chemically Induced Degradation of Disease-causing kinases by a PROteolysis Targeting Chimera?s (PROTACs) Coupled with Tumor Targeting Ligands | Dr. SABAREESH V (Co-PI) | DST-SERB | 2020-2023 (3 years) Rs. 36 Lakhs | On-going |
| 17 | Structural functional and regulatory studies of ubiquitin-conjugating enzymes involved in chromatin modification | Dr. PRAKASH KUMAR SHUKLA (PI) | DBT | 21-11-2023 (3 years) Rs. 83,16,000 | On-going |
| 18 | Development of Rapid and High Sensitivity Electrochemical Covid-19 Diagnosis Platform | Dr. Jayaprakash N.S. (Co-PI) Dr. Krishnan V (Co-PI) | ICMR | 08-02-2023 (18 months) Rs.40,27,320 | On-going |
| 19 | Combating Antimicrobial Resistance (AMR) in Vibrio sp. by targeting vibrio antibiotic resistance (var) regulon: Structural and biochemical characterization of var regulon activator and metallo-beta-lactamase in V. cholerae and V. vulnificus | Dr. DHANASINGH IMMANUEL (PI) | DST-SERB | 08-02-2023 (3 years) Rs.29,39,330 | On-going |
| 20 | Immunometabolomics in the quest for comprehending protection and pathogenesis in tuberculosis | Dr. SABAREESH V (PI) | ICMR | 20-02-2023 (3 years) Rs.27,91,000 | On-going |
Â
- Biocon Limited, India
- PALL Corporation, France
- BIA Separations, Slovenia
- LAMARK Biotech Pvt. Ltd., India
- NANENANA WELLNESS Pvt. Ltd., India
| S.No | Title | PI/Co-PI | Period & Amount | Status |
| 1 | Sekkei Bio Pvt Ltd, Bangalore, India | Dr. Sanjit Kumar | 2018-19 Rs. 3 lakhs | Completed |
| 2 | School of Biosciences, IIT Madras | Dr. N.S. Jayaprakash | 7/1/2019 Rs. 3.15 lakhs | Completed |
| 3 | Shantha Biotechniques Pvt. Ltd., Hyderabad | Dr. N.S. Jayaprakash | 2016 Rs. 3.67 lakhs | Completed |
| 4 | Indian Institute of Technology (IIT, Mumbai) | Dr. N.S. Jayaprakash | 2022 Rs. 0.52 lakhs | Completed |
| 5 | Lamark Biotech Pvt. Ltd. | Dr. N.S. Jayaprakash | 2022 Rs. 0.24 lakhs | Completed |
| 6 | NaneNana Wellness Pvt. Ltd, Delhi | Dr. N.S. Jayaprakash (Co-PI) | 2023 Rs. 6 lakhs | Completed |
| 7 | Central University of Rajasthan | Dr. N.S. Jayaprakash | 2024 Rs. 0.40 lakhs | Ongoing |
| 8 | NaneNana Wellness Pvt. Ltd, Delhi | Dr. N.S. Jayaprakash | 2025 Rs. 3 lakhs | Ongoing |
